EMA COVID-19 guidance: research and development

August 10, 2022

The European Medicines Agency (EMA) provides support to medicine developers researching and developing potential COVID-19 medicines. Dedicated guidance, rapid procedures and contact points are available.

EMA: COVID-19 guidance: research and development

Table of contents

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.

 




EMA Europe

August 10, 2022

EMA Good clinical practice (GCP) inspection procedures

The Good Clinical Practice (GCP) Inspectors Working Group has developed procedures for the coordination, preparation, conduct and reporting of GCP inspections requested by the European Medicines...

Read More
EMA Europe

August 10, 2022

EMA adopts first list of critical medicines for COVID-19

News On 7 June 2022, EMA’s Medicines Shortages Steering Group (MSSG) adopted the list of critical medicines for the COVID-19 public health emergency. The medicines included in the list are authorised...

Read More
EMA Europe

August 10, 2022

EMA Procedural guidance for variant strain(s) update to vaccines intended for protection against Human coronavirus

8 June 2022 EMA/175959/2021 Rev.2 Human Medicines Division Regulatory and procedural requirements Introduction In order to ensure the continued effectiveness of authorised COVID-19 vaccines, it may...

Read More